Holen Sie sich die Stockscreener-App
12.25
0.33%
0.04
Handel nachbörslich:
12.25
Schlusskurs vom Vortag:
$12.21
Offen:
$12.25
24-Stunden-Volumen:
1.47M
Relative Volume:
0.85
Marktkapitalisierung:
$3.85B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-18.00
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+3.03%
1M Leistung:
+2.51%
6M Leistung:
+57.46%
1J Leistung:
+51.23%
1-Tages-Spanne:
$12.17
$12.43
1-Wochen-Bereich:
$11.83
$12.43
52-Wochen-Spanne:
$6.685
$12.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.25 | 3.84B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
117.66 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.39 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.18 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
488.51 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com India
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Canada
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal (Nasdaq: AMRX) gains FDA OK for epinephrine vials in $118M U.S. market - Stock Titan
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal’s Parkinson’s drug shows positive interim results - Investing.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal announces positive interim phase 4 Elevate-Pd results with Crexont for Parkinson's disease - marketscreener.com
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
FDA approves Amneal’s generic albuterol inhaler - Investing.com
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - The Manila Times
Amneal to Participate in Upcoming Investor Conferences - The Manila Times
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
FDA Approves Amneal’s Cyclosporine Ophthalmic Emulsion 0.05% for Dry Eye - Conexiant
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
FDA approves Amneal’s generic Restasis for dry eye disease - Investing.com
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - marketscreener.com
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - The Manila Times
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies - Quiver Quantitative
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25% - simplywall.st
Looking at the Narrative for Amneal as Analyst Targets Shift After Recent Milestones - Yahoo Finance
Is Amneal Pharmaceuticals Still an Opportunity After 61% Price Surge in 2025? - Yahoo Finance
Prudential Financial Inc. Sells 65,965 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $625,000 Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Holdings Lowered by Geode Capital Management LLC - MarketBeat
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? - sharewise.com
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? - sharewise.com
Amneal gets FDA nod for Iohexol Injection - MSN
What insider trading reveals about Amneal Pharmaceuticals Inc. stockWeekly Trend Report & Smart Allocation Stock Tips - BỘ NỘI VỤ
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):